

Special Issue

Precision Tumor Therapy: The Role of PARP Inhibitors in Personalized Medicine

Message from the Guest Editor

This Special Issue aims to provide an overview of the therapeutic advances achieved with PARP inhibitors in clinical practice, to identify potential differences in activity among the various agents, and to highlight experimental or anecdotal evidence of activity in non-established indications. We invite submissions of original research articles and reviews that align with the journal's scope, which include, but are not limited to, the following:

- Molecular biology of PARP and PARP inhibitors;
- PARP inhibitors and Ovarian cancer, Breast Cancer, Cancer of the pancreas, Cancer of the prostate, Endometrial cancer;
- Non-established use of PARP inhibitors;
- Combinations of PARP inhibitors and check-point inhibitors across tumor types

Guest Editor

Dr. Christos Emmanouilides

Department of Medical Oncology, European Interbalkan Medical Center, 55535 Thessaloniki, Greece

Deadline for manuscript submissions

31 July 2026



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/251931

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).